Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1999-11-04
2003-04-08
Ulm, John (Department: 1646)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S069100, C435S320100, C536S023100
Reexamination Certificate
active
06545141
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a novel brain-specific adapter molecule, its gene, and antibodies to it.
2. Related Background Art
Nerve growth factor (NGF) is known to mainly stimulate the survival and growth of neurons of the brain and maintain the neuronal network through these activities. Neurons of the Meynert's basal ganglia, for example, integrate information from the lower regions of the cerebrum, and constantly send control signals to the cerebral cortex. These neurons receive NGF biosynthesized by neurons of the cerebral cortex, and sustain their survival (Thoenen, Trend NeuroSci., 14, 165-170, 1991, or Hatanaka, H., Cell Engineering, 9, 866-876, 1990).
Based on these findings, NGF is considered to have a high possibility for clinical use in the treatment of various neurological diseases, including recessive ones (e.g., dementia of the Alzheimer type and Parkinson's disease). Orthon et al. (J. Neural Transm. Park. Dement. Sect., 4, 79-95, 1992) have reported clinical use of NGF in patients with Alzheimer's dementia.
NGF actually transmits necessary signals into cells through NGF receptors, and studies of the pathways for the signals are under way (for example, Heumann, Current opinion in Neurobiology, 4, 668-679, 1994). Findings to be obtained through these studies are expected to serve for the direct clinical use of NGF in treating neurological diseases. In the diagnosis and treatment of cancer which abnormalities in growth factors similarly take a great part in, the achievements of researches on the signaling pathways of growth factors have reached the level of clinical application (Nikkei Biotechnology, 8-28, 2, 1995).
SUMMARY OF THE INVENTION
An object of the present invention is to search for and isolate a novel factor involved in the signaling pathways in neurons of the brain (e.g., the signaling pathways within the neurons NGF acts on).
Another object of the invention is to provide means of measuring tyrosine kinase activity in a cell or tissue by use of the novel factor (FC99 protein), the gene (FC99 gene) encoding it, and antibodies to it claimed in the invention.
The present invention will be more fully understood from the detailed description given hereinbelow and the accompanying drawings, which are given by way of illustration only and are not to be considered as limiting the present invention.
Further scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will be apparent to those skilled in the art from this detailed description.
REFERENCES:
Nakamura, T. et al., N-Shc: A neural-specific adapter molecule that mediates signaling from neurotrophin-Trk to Ras-MAPK pathway, Oncogene, 13 (6). 1996 1111-1112.
Pelicci, G. et al., A family of Shc related protein with conserved PTB, CH1 and SH2 regions, Oncogene, 13 (3) 1996 633-641.
Rudinger, “Peptide Hormones”, (ed. Parsons), University Park Press, Baltimore, pp. 107, 1976.
Salgaller et al., “Cancer Immunology Immunother.”, vol. 39, pp. 105-116, 1994.
Pelicci et al., A Novel Transforming Protein (SHC) with an SH2 Domain Is Implicated in Mitogenic Signal Transduction, Cell, vol. 70, 93-104, Jul. 10, 1992.
Pelicci et al., Constitutive phosphorylation of Shc proteins in human tumors, Oncogene (1995) 11, 899-907.
Obermeier et al., Neuronal differentiation signals are controlled by nerve growth factor receptor/Trk binding sites for SHC and PLC, The EMBO Journal, vol. 13, No. 7, pp. 1585-1590, 1994.
Blaikie et al., A Region in Shc distinct from the SH2 domain can bind Tyrosine-Phosphorylated growth factor receptors, J. Biol. Chem, Dec. 23, 1994 269 (51).
Pawson, T., Protein Modules and signalling networks, Nature, Feb. 16, 1995, 373 (6515) P573-80.
O'Bryan J. P. et al., A mammalian adapter protein with conserved Src homology 2 and phosphotyrosine-binding domains is related to Shc and is specifically expressed in the brain, Proceedings of the Nat'l Acad. of Sci. of the U.S. of A., 93 (7). 1996 2729-2734.
Chernyshev Olga N.
McDermott & Will & Emery
Sumitomo Electric Industries Ltd.
Ulm John
LandOfFree
Brain-specific adapter molecule, gene thereof, and antibody... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Brain-specific adapter molecule, gene thereof, and antibody..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Brain-specific adapter molecule, gene thereof, and antibody... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3061707